Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen

NCT02481310 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT02481310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02481310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
Lead sponsor
Northwestern University
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 28, 2015
Completion date
July 31, 2024
Enrollment
38 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adult burkitt lymphoma, b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and burkitt lymphoma, diffuse large b-cell lymphoma, myc gene mutation, plasmablastic lymphoma